Page 16 - Jason Ehrlich News Today

Press release content from PR Newswire. The AP news staff was not involved in its creation.

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...

Kodiak Sciences Inc. (NASDAQ:KOD – Get Rating) insider Jason Ehrlich sold 2,282 shares of the firm’s stock in a transaction on Friday, June 17th. The shares were sold at an average price of $7.02, for a total transaction of $16,019.64. Following the completion of the transaction, the insider now owns 56,920 shares in the company, […]

Kodiak Sciences (NASDAQ:KOD – Get Rating)‘s stock had its “buy” rating reiterated by equities research analysts at Chardan Capital in a note issued to investors on Monday, Zacks.com reports. Other equities research analysts have also recently issued research reports about the company. Barclays dropped their price objective on Kodiak Sciences from $81.00 to $50.00 and […]

Kodiak Sciences (NASDAQ:KOD – Get Rating) had its price target cut by Morgan Stanley from $17.00 to $12.00 in a report issued on Tuesday, MarketBeat reports. They currently have an equal weight rating on the stock. Several other analysts have also recently issued reports on KOD. JPMorgan Chase & Co. cut Kodiak Sciences from an […]

Analysts expect Kodiak Sciences Inc. (NASDAQ:KOD – Get Rating) to post earnings per share of ($1.47) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Kodiak Sciences’ earnings. The highest EPS estimate is ($0.73) and the lowest is ($1.80). Kodiak Sciences reported earnings per share of ($0.98) during the […]

Kodiak Sciences (NASDAQ:KOD – Get Rating) had its price target trimmed by Roth Capital from $149.00 to $75.00 in a research note published on Monday, The Fly reports. KOD has been the subject of several other research reports. Barclays cut their price target on Kodiak Sciences from $81.00 to $50.00 and set an underweight rating […]

PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical... | February 23, 2022

/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3...